A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

Phase 3 Completed 100 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to document the long term safety of a long-acting injectable formulation of risperidone in the treatment of patients with schizophrenia who have previously been treated with long-acting risperidone. Efficacy will also be evaluated.

Timeline

Start: 2001-11
Primary completion: —
Completion: 2004-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Risperidone	Other / unclassified	25 mg	Intramuscular
Subject	Risperidone	Other / unclassified	50 mg	Intramuscular

A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

Summary

Timeline

Drugs

Indications